Monopar Therapeutics (MNPR) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Monopar Therapeutics reported revenue of $0. Net income was -$13.7M. Operating activities generated -$12.2M of cash. At fiscal year end, Monopar Therapeutics held $140.7M in total assets against $2.9M in total liabilities, including $61.8M of cash and equivalents.
Open the full interactive Monopar Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Monopar Therapeutics Key Stats
| Share Price | $72.08 |
|---|---|
| Market Cap | $615.7M |
| 52-Week Range | $50.12 – $123.84 |
| Shares Outstanding | 8.5 million (basic, 2026 Q2) |
Monopar Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$6.5M | -$9.1M | -$10.5M | -$8.8M | -$16.2M | -$16.7M |
| Pre-Tax Income | -$6.3M | -$9.1M | -$10.5M | -$8.4M | -$15.6M | -$13.7M |
| Income Tax | $18,361 | $0 | $0 | $800 | $800 | $800 |
| Net Income | -$6.3M | -$9.1M | -$10.5M | -$8.4M | -$15.6M | -$13.7M |
| Diluted EPS | -$2.90 | -$3.65 | — | — | — | — |
Monopar Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.4M | -$5.2M | -$3.9M | -$5.3M |
Monopar Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.7M | $20.3M | $8.2M | $7.3M | $45.8M | $61.8M |
| Current Assets | $16.8M | $20.5M | $13.2M | $7.3M | $60.3M | $140.5M |
| Total Assets | $16.9M | $20.5M | $13.2M | $7.3M | $60.3M | $140.7M |
| Current Liabilities | $1.2M | — | $3.1M | $1.8M | — | $2.7M |
| Total Liabilities | $1.2M | $1.6M | $3.1M | $1.8M | $5.3M | $2.9M |
| Shareholders' Equity | $15.7M | $18.9M | $10.1M | $5.6M | $55.0M | $137.8M |
Monopar Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$4.7M | $7.3M | -$7.2M | -$7.9M | -$6.4M | -$12.2M |
| Cash From Investing | $3,334 | — | -$4.9M | $4.9M | -$14.3M | -$63.5M |
| Cash From Financing | $8.2M | $10.9M | $32,873 | $2.0M | $59.3M | $91.6M |
Figures from Monopar Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Monopar Therapeutics financials page for every line item.
Monopar Therapeutics Company Profile
| Ticker | MNPR |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Wilmette, Illinois |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001645469 |
Frequently Asked Questions
What was Monopar Therapeutics' revenue in fiscal 2025?
Monopar Therapeutics (MNPR) reported revenue of $0 for fiscal 2025.
What is Monopar Therapeutics' annual revenue history?
Monopar Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Monopar Therapeutics' net income in fiscal 2025?
Monopar Therapeutics reported net income of -$13.7M for fiscal 2025.
What was Monopar Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Monopar Therapeutics reported revenue of $0.
How many shares of Monopar Therapeutics are outstanding?
Monopar Therapeutics reported a weighted average of 8.5 million basic shares outstanding in 2026 Q2.
What is Monopar Therapeutics' market cap?
Based on its latest closing price, Monopar Therapeutics (MNPR) has a market capitalization of about $615.7M.
When does Monopar Therapeutics' fiscal year end?
Monopar Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Monopar Therapeutics headquartered?
Monopar Therapeutics lists its business address in Wilmette, Illinois in its SEC filings.